체코 - 체코어 - SUKL (Státní ústav pro kontrolu léčiv)

indivior europe limited, dublin array - 4670 buprenorfin-hydrochlorid - sublingvální tableta - 8mg - buprenorfin

유럽 연합 - 체코어 - EMA (European Medicines Agency)

fresenius kabi deutschland gmbh - tocilizumab - arthritis, rheumatoid; cytokine release syndrome; arthritis, juvenile rheumatoid; covid-19 virus infection; giant cell arteritis - imunosupresiva - tyenne, in combination with methotrexate (mtx), is indicated for- the treatment of severe, active and progressive rheumatoid arthritis (ra) in adults not previously treated with mtx. - the treatment of moderate to severe active ra in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying anti-rheumatic drugs (dmards) or tumour necrosis factor (tnf) antagonists. in these patients, tyenne can be given as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. tocilizumab has been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function when given in combination with methotrexate. tyenne is indicated for the treatment of coronavirus disease 2019 (covid-19) in adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation. tyenne is indicated for the treatment of active systemic juvenile idiopathic arthritis (sjia) in patients 1 year of age and older, who have responded inadequately to previous therapy with nsaids and systemic corticosteroids. tyenne can be given as monotherapy (in case of intolerance to mtx or where treatment with mtx is inappropriate) or in combination with mtx. tyenne in combination with methotrexate (mtx) is indicated for the treatment of juvenile idiopathic polyarthritis (pjia; rheumatoid factor positive or negative and extended oligoarthritis) in patients 2 years of age and older, who have responded inadequately to previous therapy with mtx. tyenne can be given as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. tyenne is indicated for the treatment of chimeric antigen receptor (car) t cell-induced severe or life-threatening cytokine release syndrome (crs) in adults and paediatric patients 2 years of age and older. tyenne is indicated for the treatment of giant cell arteritis (gca) in adult patients.

체코 - 체코어 - SUKL (Státní ústav pro kontrolu léčiv)

pharmagen cz s.r.o., praha array - 10417 ondansetron - tableta dispergovatelná v ústech - 8mg - ondansetron

체코 - 체코어 - SUKL (Státní ústav pro kontrolu léčiv)

b. braun melsungen ag, melsungen array - 10418 dihydrÁt ondansetron-hydrochloridu - injekční roztok - 2mg/ml - ondansetron

체코 - 체코어 - SUKL (Státní ústav pro kontrolu léčiv)

fresenius kabi deutschland gmbh, bad homburg array - 10418 dihydrÁt ondansetron-hydrochloridu - infuzní roztok - 0,08mg/ml - ondansetron

체코 - 체코어 - SUKL (Státní ústav pro kontrolu léčiv)

fresenius kabi deutschland gmbh, bad homburg array - 10418 dihydrÁt ondansetron-hydrochloridu - infuzní roztok - 0,16mg/ml - ondansetron

체코 - 체코어 - SUKL (Státní ústav pro kontrolu léčiv)

fresenius kabi deutschland gmbh, bad homburg array - 10418 dihydrÁt ondansetron-hydrochloridu - injekční roztok - 2mg/ml - ondansetron

체코 - 체코어 - SUKL (Státní ústav pro kontrolu léčiv)

as kalceks, riga array - 10418 dihydrÁt ondansetron-hydrochloridu - injekční/infuzní roztok - 2mg/ml - ondansetron

체코 - 체코어 - SUKL (Státní ústav pro kontrolu léčiv)

teva pharmaceuticals cr, s.r.o., praha array - 10418 dihydrÁt ondansetron-hydrochloridu - potahovaná tableta - 8mg - ondansetron

체코 - 체코어 - SUKL (Státní ústav pro kontrolu léčiv)

b. braun melsungen ag, melsungen array - 14843 remifentanil-hydrochlorid - prášek pro koncentrát pro injekční/infuzní roztok - 1mg - remifentanil